Metabolomics in monitoring kidney transplants

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 6, 2006, Pages 637-642

  Wishart, David S ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Kidney transplant; Metabolites; Metabolomics; Renal function

Indexed keywords

AM 19; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DRUG METABOLITE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; METABOLITE; METABOLOMICS; MONITORING; ORGAN INJURY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; URINALYSIS;

BIOLOGICAL MARKERS; GENOMICS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MONITORING, PHYSIOLOGIC; PROTEOMICS; REPERFUSION INJURY; TRANSPLANTS;

EID: 33750216997     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000247499.64291.52     Document Type: Review

References (51)

1. Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. Surg Forum 1955; 6:432-437.
2. Murray JE, Barnes BA, Atkinson JC. Fifth report of the Human Kidney Transplant Registry. Transplantation 1967; 5:752-755.
3. Cecka JM. The UNOS Scientific Renal Transplant Registry - 2000. Clin Transpl 2000; 1-18.
4. CeckaJM.TheOPTN/UNOSrenal transplant registry. Clin Transpl 2004;1-16.
5. Oberholzer J, Testa G, Sankary H, et al. Kidney transplantation at the University of Illinois at Chicago from 1988-2004. Clin Transpl 2004; 143-149.
6. Djamali A, Premasathian N, Pirsch JD. Outcomes in kidney transplantation. Semin Nephrol 2003; 23:306-316.
7. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006; 69:655-662. This nice review describes the emerging importance of the BK (polyoma) virus in causing posttransplant dysfunction.
8. Veronese FV, Manfro RC, Roman FR, et al. Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 2005; 19:518-521. The authors use a multipathologist assessment to highlight the problems associated with using the Banff classification protocol in identifying and classifying transplant rejection events by histopathology.
9. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15:219-227.
10. O'Riordan E, Goligorsky MS. Emerging studies of the urinary proteome: the end of the beginning? Curr Opin Nephrol Hypertens 2005; 14:579-585. This is a useful review about the emerging importance and untapped potential of urinary proteomics in monitoring renal function.
11. Eikmans M, Roos-van Groningen MC, Sijpkens YW, et al. Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. J Am Soc Nephrol 2005; 16:3771-3786. This is a nice example of how transcriptomics and microarrays can be used to identify specific biomarkers for predicting transplant outcomes.
12. Wishart DS. Metabolomics: the principles and applications to transplantation. Am J Transplant 2005; 5:2814-2820. This is the first review published on the topic of metabolomics and organ transplantation. It provides a good historical overview of metabolic profiling being applied to monitor a wide range of solid organ transplants.
13. Drysdale R, Bayraktaroglu L. Current awareness. Yeast 2000; 17:159-166.
14. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29:1181-1189.
15. Thompson JA, Markey SP. Quantitative metabolic profiling of urinary organic acids by gas chromatography-mass spectrometry: comparison of isolation methods. Anal Chem 1975; 47:1313-1321.
16. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130:606-625. This is a superb summary of the technologies and general methodological approaches being used in metabolomics. It is well written and very comprehensive.
17. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004; 9:1-31.
18. Smith IC, Baert RL. Medical diagnosis by high resolution NMR of human specimens. IUBMB Life 2003; 55:273-277.
19. Wishart DS, Querengesser LMM, Lefebvre BA, et al. Magnetic resonance diagnostics: a new technology for high-throughput clinical diagnostics. Clin Chem 2001; 47:1918-1921.
20. Bell JD, Lee JA, Lee HA, et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096:101-107.
21. Serkova N, Fuller TF, Klawitter J, et al. H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 2005; 67:1142-1151. This well designed and informative study identifies, quantifies and explains the origins of many endogenous metabolites arising from ischemia-repurfusion injury. It is an excellent example of a modern metabolomic study applied to kidney transplantation.
22. Fuller TF, Serkova N, Niemann CU, Freise CE. Influence of donor pretreatment with N-acetylcysteine on ischemia/reperfusion injury in rat kidney grafts. J Urol 2004; 171:1296-1300.
23. Hauet T, Baumert H, Gibelin H, et al. Noninvasive monitoring of citrate, acetate, lactate and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury. Cryobiology 2000; 41:280-291.
24. Domanski L, Safranow K, Dolegowska B, et al. Hypoxanthine as a graft ischemia marker stimulates catalase activity in the renal vein during reperfusion in humans. Transplant Proc 2006; 38:35-38. This solid paper describes the identification and tracking of serum hypoxanthine and inosine as markers for ischemic damage.
25. Al Banchaabouchi M, Marescau B, D'Hooge R, et al. Biochemical and histopathological changes in nephrectomized mice. Metabolism 1998; 47:355-361.
26. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6:37-47. This paper reviews the status of the pharmacogenomics and pharmacokinetics associated with CYP3A variants in calcineurin inhibitor metabolism.
27. Vollenbroeker B, Koch JH, Fobker M, et al. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc 2005; 37:1741-1744. The authors describe an mass spectrometry-based method that allows detection and quantification of cyclosporine and five of its metabolites. They also associate outcome with the presence of a particular CsA metabolite.
28. Annesley TM, Clayton LT. Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry. Clin Chem 2005; 51:872-877. This paper outlines an mass spectrometry-based method for the detection and quantification of mycophenolate mofetil and its metabolites that is more accurate and sensitive than current immunoassays.
29. Lenz EM, Bright J, Knight R, et al. Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004; 35:599-608.
30. Serkova NJ, Christians U. Biomarkers for toxidynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005; 27:733-737. This is another excellent example that illustrates the power of using NMR to identify and quantify changes in endogenous metabolites associated with calcineurin inhibitors.
31. Stapenhorst L, Sassen R, Beck B, et al. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005; 20:652-656. The authors describe and quantify the reduction in citrate and the increase in oxalate that appears to arise from CsA toxicity.
32. Tse KC, Lam MF, Yip PS, et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004; 18:274-280.
33. Moreno JM, Ruiz MC, Ruiz N, et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005; 37:1428-1430. This describes and quantifies the reduction in malondialdehyde levels and elevated glutathione peroxidase activity as a result of immunosuppressive therapy.
34. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16:3128-3135. This highlights the problems of immunosuppression-induced diabetes and the fact that neither CsA, tacrolimus or sirolimus appear to offer any improvement.
35. Kanbay M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005; 37:3119-3120. The authors measured the incidence of elevated levels of uric acid found in renal transplant recipients and noted that both CsA and tacrolimus lead to comparable levels of serum uric acid.
36. Perico N, Codreanu I, Caruso M, Remuzzi G. Hyperuricemia in kidney transplantation. Contrib Nephrol 2005; 147:124-131. This nice review explains the importance of uric acid in contributing to transplant dysfunction.
37. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005; 80:1565-1571. This well controlled and statistically robust study reported the generally high incidence of elevated uric acid levels in renal transplant patients.
38. Wong W, Tolkoff-Rubin N, Delmonico FL, et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004; 18:341-348.
39. Foxall PJ, Mellotte GJ, Bending MR, et al. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int 1993; 43:234-245.
40. Le Moyec L, Pruna A, Eugene M, et al. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 1993; 65:433-439.
41. Knoflach A, Binswanger U. Serum hippuric acid concentration in renal allograft rejection, ureter obstruction and tubular necrosis. Transpl Int 1994; 7:17-21.
42. Jankowski J, van der Giet M, Jankowski V, et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112:256-264.
43. Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 2006; 15:314-320.
44. Dedeoglu IO, Feld LG. Decreased urinary excretion of nitric oxide in acute rejection episodes in pediatric renal allograft recipients. Transplantation 1996; 62:1936-1968.
45. Yatzidis H. Oral supplement of six selective amino acids arrest progression renal failure in uremic patients. Int Urol Nephrol 2004; 36:591-598.
46. Albrecht EW, van Goor H, Smit-van Oosten A, Stegeman CA. Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. Nitric Oxide 2003; 8:53-58.
47. Holmes E, Nicholls AW, Lindon JC, et al. Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Toxicol 2000; 13:471-478.
48. Williams RE, Major H, Lock EA, et al. D-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology 2005; 207:179-190. This is an interesting example of an mass spectrometry-based metabolomic study to identify the metabolic consequences of focal kidney lesions brought on by the nephrotoxin D-serine.
49. Lenz EM, Bright J, Knight R, et al. Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 2005; 10:173-187. This describes a well integrated (NMR and mass spectrometry) metabolomic study aimed at identifying the metabolic consequences of localized kidney damage brought on by genatamicin, a nephrotoxin.
50. Lenz EM, Bright J, Knight R, et al. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004; 129:535-541.
51. American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005; 16:1886-1903. This report outlines the strategic research goals and research tools that will facilitate renal studies for the next decade.